Trustmark National Bank Trust Department Sells 19,221 Shares of Bristol-Myers Squibb (NYSE:BMY)

Trustmark National Bank Trust Department lowered its position in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 33.4% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 38,370 shares of the biopharmaceutical company's stock after selling 19,221 shares during the quarter. Trustmark National Bank Trust Department's holdings in Bristol-Myers Squibb were worth $1,985,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the company. Bessemer Group Inc. lifted its position in shares of Bristol-Myers Squibb by 16.3% in the 1st quarter. Bessemer Group Inc. now owns 159,066 shares of the biopharmaceutical company's stock worth $8,625,000 after buying an additional 22,286 shares during the last quarter. CreativeOne Wealth LLC lifted its holdings in Bristol-Myers Squibb by 60.1% in the first quarter. CreativeOne Wealth LLC now owns 28,536 shares of the biopharmaceutical company's stock worth $1,548,000 after acquiring an additional 10,709 shares during the last quarter. Axxcess Wealth Management LLC grew its holdings in shares of Bristol-Myers Squibb by 22.3% during the first quarter. Axxcess Wealth Management LLC now owns 73,554 shares of the biopharmaceutical company's stock valued at $3,989,000 after purchasing an additional 13,414 shares during the last quarter. Advisors Asset Management Inc. raised its position in shares of Bristol-Myers Squibb by 46.4% during the 1st quarter. Advisors Asset Management Inc. now owns 134,138 shares of the biopharmaceutical company's stock worth $7,274,000 after purchasing an additional 42,509 shares during the period. Finally, Sheaff Brock Investment Advisors LLC lifted its holdings in shares of Bristol-Myers Squibb by 2.4% in the 1st quarter. Sheaff Brock Investment Advisors LLC now owns 33,954 shares of the biopharmaceutical company's stock worth $1,841,000 after purchasing an additional 808 shares during the last quarter. Institutional investors own 76.41% of the company's stock.

Bristol-Myers Squibb Stock Up 0.6 %

Shares of NYSE BMY traded up $0.35 during trading on Thursday, hitting $58.23. The company had a trading volume of 7,412,206 shares, compared to its average volume of 14,395,206. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $61.08. The company has a debt-to-equity ratio of 2.83, a current ratio of 1.24 and a quick ratio of 1.09. The business's 50-day moving average is $53.26 and its 200 day moving average is $47.54.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, beating analysts' consensus estimates of $1.49 by $0.31. The company had revenue of $11.89 billion during the quarter, compared to analyst estimates of $11.26 billion. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The business's quarterly revenue was up 8.4% on a year-over-year basis. During the same period in the prior year, the firm earned $2.00 earnings per share. As a group, research analysts forecast that Bristol-Myers Squibb will post 0.93 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, November 1st. Stockholders of record on Friday, October 4th were issued a $0.60 dividend. The ex-dividend date of this dividend was Friday, October 4th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.12%. Bristol-Myers Squibb's payout ratio is currently -66.85%.

Insider Transactions at Bristol-Myers Squibb

In related news, EVP Samit Hirawat bought 1,830 shares of the business's stock in a transaction on Friday, November 1st. The stock was bought at an average price of $54.67 per share, for a total transaction of $100,046.10. Following the transaction, the executive vice president now directly owns 62,109 shares in the company, valued at $3,395,499.03. This represents a 3.04 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Phil M. Holzer sold 700 shares of the business's stock in a transaction on Monday, November 4th. The shares were sold at an average price of $55.62, for a total transaction of $38,934.00. Following the transaction, the senior vice president now owns 11,760 shares in the company, valued at approximately $654,091.20. This represents a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.09% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Barclays upped their price objective on Bristol-Myers Squibb from $42.00 to $43.00 and gave the stock an "underweight" rating in a research note on Monday, October 7th. Daiwa Capital Markets raised shares of Bristol-Myers Squibb from a "neutral" rating to an "outperform" rating in a report on Wednesday, November 13th. Morgan Stanley boosted their target price on shares of Bristol-Myers Squibb from $36.00 to $39.00 and gave the company an "underweight" rating in a research note on Tuesday, November 12th. Leerink Partnrs upgraded shares of Bristol-Myers Squibb from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, November 12th. Finally, Wolfe Research started coverage on Bristol-Myers Squibb in a report on Friday, November 15th. They set a "peer perform" rating on the stock. Two investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating, two have assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $54.07.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.